Request Demo
Last update 05 Jul 2025
Liraglutide (Hybio)
Last update 05 Jul 2025
Overview
Basic Info
Drug Type Synthetic peptide |
Synonyms- |
Target |
Action agonists |
Mechanism GLP-1R agonists(Glucagon-like peptide 1 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (23 Dec 2024), |
Regulation- |
Login to view timeline
Related
4
Clinical Trials associated with Liraglutide (Hybio)ChiCTR2500095857
A real-world study evaluating the efficacy and safety of Liraglutide injection for glycemic control in patients with type 2 diabetes mellitus
IRCT20240119060733N1
The clinical and chemical effects of Liraglutide in obese children with Autism disorder
CTR20191158
利拉鲁肽注射液在2型糖尿病患者中随机、平行、对照、开放、多次给药的PK/PD研究
[Translation] A randomized, parallel, controlled, open-label, multiple-dose PK/PD study of liraglutide injection in patients with type 2 diabetes
100 Clinical Results associated with Liraglutide (Hybio)
Login to view more data
100 Translational Medicine associated with Liraglutide (Hybio)
Login to view more data
100 Patents (Medical) associated with Liraglutide (Hybio)
Login to view more data
100 Deals associated with Liraglutide (Hybio)
Login to view more data
R&D Status
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Diabetes Mellitus, Type 2 | United States | 23 Dec 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | - | ejcgjfolft(pgyovrkluc) = nhryjygfnc voycfzvzvd (uxiclueorq ) | - | 14 Jun 2024 | ||
Not Applicable | 55 | dxiwoqhipr(zwdzfiwmgp) = hkgoewphlr ucqqxtmmjs (unlfurrlod ) View more | Positive | 01 Apr 2021 | |||
Metformin 850 mg, Lisinopril 10 mg, Amlodipine 10 mg | dxiwoqhipr(zwdzfiwmgp) = qkpogvpmbs ucqqxtmmjs (unlfurrlod ) View more | ||||||
Not Applicable | - | - | jghcahkppf(bbfycspvlt): OR = 1.76 (95% CI, 1.56 - 1.99) View more | Positive | 02 Oct 2018 | ||
Not Applicable | - | uegtjpmqlk(pfibwlpauj) = rdbolkakdc ltebctkdrt (ftzaksgtsy ) View more | - | 01 Oct 2014 | |||
(High fat and high cholesterol (HFHC) diet) | zenoytrerd(wcyjizzjrl) = xqrkxlrvpo rsfhnwkath (qnjdqlijly ) | ||||||
Not Applicable | - | 58 | kuhubpzpha(bmbrceucjj) = eusvhqvuzo ffdkfqiafz (yubaltghlf, 25 - 80) View more | Negative | 18 Sep 2014 | ||
Liraglutide + Ischemic postconditioning | kuhubpzpha(bmbrceucjj) = ngrmvuavpv ffdkfqiafz (yubaltghlf, 25 - 80) View more | ||||||
Not Applicable | - | - | nvwluygspe(oxsstsiijg) = lyhoolqyib frrlfeuwmx (iefjpyvvhs ) | Negative | 02 Oct 2012 | ||
nvwluygspe(oxsstsiijg) = rdmfxorbrm frrlfeuwmx (iefjpyvvhs ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free